(FLGT) Fulgent Genetics - Overview
Stock: Genetic Tests, Molecular Diagnostics, Pathology Tests, Oncology Services
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 41.0% |
| Relative Tail Risk | -12.6% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.88 |
| Alpha | 27.96 |
| Character TTM | |
|---|---|
| Beta | 0.618 |
| Beta Downside | 0.386 |
| Drawdowns 3y | |
|---|---|
| Max DD | 62.56% |
| CAGR/Max DD | -0.17 |
Description: FLGT Fulgent Genetics December 25, 2025
Fulgent Genetics, Inc. (NASDAQ: FLGT) is a U.S.–based provider of clinical diagnostic and therapeutic development services, offering a broad portfolio that spans molecular and genetic testing, anatomic pathology (including GI, dermatopathology, urologic, breast, neuro, and hematopathology), oncology assays, and sequencer services for hereditary cancer and reproductive health. The firm also runs a proprietary “picture genetics” platform that combines gene probes, data-suppression algorithms, adaptive-learning software, and a custom laboratory information management system to pinpoint health markers in individual DNA.
Beyond diagnostics, Fulgent leverages a nano-encapsulation and targeted-therapy platform to develop cancer drug candidates aimed at improving therapeutic windows and pharmacokinetic profiles. Its customer base includes insurers, hospitals, medical labs, government agencies, payors, municipalities, large corporations, and individual patients. The company rebranded from Fulgent Diagnostics to Fulgent Genetics in August 2016 and has been headquartered in El Monte, California since its 2011 founding.
Key recent metrics: FY 2023 revenue reached approximately $209 million, reflecting ~20 % year-over-year growth; gross margins hovered near 71 %; and the nano-encapsulation pipeline now contains three IND-ready candidates targeting solid-tumor indications. Primary economic drivers are the expanding demand for personalized medicine, rising cancer-screening volumes, and favorable reimbursement trends for molecular diagnostics-factors that have lifted the health-care services sub-industry’s average revenue growth to roughly 12 % annually. For a deeper dive into FLGT’s valuation metrics, you might explore the analysis on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -43.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.02 > 0.02 and ΔFCF/TA 0.69 > 1.0 |
| NWC/Revenue: 137.8% < 20% (prev 90.92%; Δ 46.92% < -1%) |
| CFO/TA 0.00 > 3% & CFO 1.52m > Net Income -43.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.01 > 1.5 & < 3 |
| Outstanding Shares: last quarter (30.7m) vs 12m ago 1.09% < -2% |
| Gross Margin: 41.24% > 18% (prev 0.36%; Δ 4088 % > 0.5%) |
| Asset Turnover: 25.78% > 50% (prev 22.51%; Δ 3.26% > 0%) |
| Interest Coverage Ratio: -206.2 > 6 (EBITDA TTM -31.3m / Interest Expense TTM 269.0k) |
Altman Z'' 9.80
| A: 0.36 (Total Current Assets 507.4m - Total Current Liabilities 72.4m) / Total Assets 1.21b |
| B: 0.46 (Retained Earnings 553.4m / Total Assets 1.21b) |
| C: -0.05 (EBIT TTM -55.5m / Avg Total Assets 1.22b) |
| D: 5.97 (Book Value of Equity 560.2m / Total Liabilities 93.8m) |
| Altman-Z'' Score: 9.80 = AAA |
Beneish M -3.05
| DSRI: 1.21 (Receivables 78.7m/57.3m, Revenue 315.5m/277.8m) |
| GMI: 0.88 (GM 41.24% / 36.22%) |
| AQI: 0.76 (AQ_t 0.49 / AQ_t-1 0.65) |
| SGI: 1.14 (Revenue 315.5m / 277.8m) |
| TATA: -0.04 (NI -43.0m - CFO 1.52m) / TA 1.21b) |
| Beneish M-Score: -3.05 (Cap -4..+1) = AA |
What is the price of FLGT shares?
Over the past week, the price has changed by -10.53%, over one month by -9.81%, over three months by +5.06% and over the past year by +41.46%.
Is FLGT a buy, sell or hold?
- StrongBuy: 0
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the FLGT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 33.7 | 43.6% |
| Analysts Target Price | 33.7 | 43.6% |
| ValueRay Target Price | 23.4 | -0% |
FLGT Fundamental Data Overview February 02, 2026
P/S = 2.5667
P/B = 0.7193
P/EG = 1.32
Revenue TTM = 315.5m USD
EBIT TTM = -55.5m USD
EBITDA TTM = -31.3m USD
Long Term Debt = 1.96m USD (from longTermDebt, last quarter)
Short Term Debt = 1.96m USD (from shortTermDebt, last quarter)
Debt = 7.54m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -110.1m USD (from netDebt column, last quarter)
Enterprise Value = 441.6m USD (809.9m + Debt 7.54m - CCE 375.8m)
Interest Coverage Ratio = -206.2 (Ebit TTM -55.5m / Interest Expense TTM 269.0k)
EV/FCF = -22.25x (Enterprise Value 441.6m / FCF TTM -19.8m)
FCF Yield = -4.49% (FCF TTM -19.8m / Enterprise Value 441.6m)
FCF Margin = -6.29% (FCF TTM -19.8m / Revenue TTM 315.5m)
Net Margin = -13.62% (Net Income TTM -43.0m / Revenue TTM 315.5m)
Gross Margin = 41.24% ((Revenue TTM 315.5m - Cost of Revenue TTM 185.4m) / Revenue TTM)
Gross Margin QoQ = 42.24% (prev 42.10%)
Tobins Q-Ratio = 0.36 (Enterprise Value 441.6m / Total Assets 1.21b)
Interest Expense / Debt = 0.37% (Interest Expense 28.0k / Debt 7.54m)
Taxrate = 21.0% (US default 21%)
NOPAT = -43.8m (EBIT -55.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.01 (Total Current Assets 507.4m / Total Current Liabilities 72.4m)
Debt / Equity = 0.01 (Debt 7.54m / totalStockholderEquity, last quarter 1.13b)
Debt / EBITDA = 3.52 (negative EBITDA) (Net Debt -110.1m / EBITDA -31.3m)
Debt / FCF = 5.55 (negative FCF - burning cash) (Net Debt -110.1m / FCF TTM -19.8m)
Total Stockholder Equity = 1.13b (last 4 quarters mean from totalStockholderEquity)
RoA = -3.51% (Net Income -43.0m / Total Assets 1.21b)
RoE = -3.82% (Net Income TTM -43.0m / Total Stockholder Equity 1.13b)
RoCE = -4.92% (EBIT -55.5m / Capital Employed (Equity 1.13b + L.T.Debt 1.96m))
RoIC = -3.88% (negative operating profit) (NOPAT -43.8m / Invested Capital 1.13b)
WACC = 8.12% (E(809.9m)/V(817.4m) * Re(8.19%) + D(7.54m)/V(817.4m) * Rd(0.37%) * (1-Tc(0.21)))
Discount Rate = 8.19% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.63%
Fair Price DCF = unknown (Cash Flow -19.8m)
EPS Correlation: -45.17 | EPS CAGR: -44.13% | SUE: 0.19 | # QB: 0
Revenue Correlation: -62.17 | Revenue CAGR: -25.35% | SUE: 0.37 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.11 | Chg30d=+0.000 | Revisions Net=-3 | Analysts=3
EPS next Year (2026-12-31): EPS=-0.32 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=-214.4% | Growth Revenue=+9.8%